Summary
This study aims to understand how a new anti-cancer drug called ATNM-400 behaves in the body, to determine a safe dose range, and to assess its early signs of anti-tumour activity. ATNM-400 is also known as [²²5Ac]-barecetamab-DOTA.
Who is it for?
You may be eligible for this study if you are:
- aged 18 years or older,
- have been diagnosed with metastatic prostate cancer that has not responded to surgery,
- have undergone at least one previous round of chemotherapy.
Study details
Participants who choose to enrol in this study may be invited to participate in one of three parts.
- Part A - Participants will have a dose of [89Zr]-barecetamab-DFO injected into a vein and will then undergo PET-CT imaging.
- [89Zr]-barecetamab-DFO is a non-therapeutic version of ATNM-400 and is used with PET/CT scans to show how it finds and attaches to the tumour, and how it moves through the body.
- These participants will also be asked to provide blood samples for up to 6 hours after their injection.
- Part B - Participants will be given a dose of ATNM-400 injected into a vein once every 6 weeks.
- If participants don't experience any extreme side effects, they may have this treatment repeated up to 4 times.
- Different groups of participants will be enrolled to assess higher doses of ATNM-400 for this part.
- Part C - Participants will be give a dose of ATNM-400 injected into a vein once every 6 weeks.
- If participants don't experience any extreme side effects, they may have this treatment repeated for up to 1 year.
Participants in Part B and C will also be asked to provide further blood samples while receiving ATNM-400 and to undergo additional PET-CT and possibly MR imaging.
It is hoped this research will determine if ATNM-400 anti-cancer treatment could be developed further for patients with advanced prostate cancer who have limited treatment options.